HomeWebinarsHow to Accelerate and Enhance ADC Therapies

How to Accelerate and Enhance ADC Therapies


The ADCore product line offers versatile intermediates that simplify the synthesis of common ADC payloads (dolastatins, maytansinoids, and PBDs) by greatly reducing the number of synthetic steps. This translates to savings in development and manufacturing costs and shorter timelines to the clinic.

To address the poor solubility of many ADC payloads, ChetoSensar™ was developed to significantly increase the hydrophilicity of the drug linker, which has been shown to also substantially increase the efficacy of ADCs and broaden the therapeutic window. Lastly, the ADC Express™ service leverages conjugation chemistry and analytical expertise to help design and quickly synthesize sets of potential ADC therapies suitable for screening to simplify candidate selection and get ADC therapies to market faster.

In this webinar, you will learn about:

  • The advantages of using advanced intermediates to develop ADC therapies
  • How to increase ADC solubility and efficiency
  • Fast, small-scale ADC library generation
  • Seamless supply chain with reduced complexity and regulatory support


Ross Bemowski, Ph.D.

Ross Bemowski, Ph.D.


Associate Director of Analytical Development

Ross Bemowski oversees the analytical development for new API products coming out of the API R&D group located in Madison, WI. He is also the technical lead for Chetosensar™ technology platform. Prior to this, he was an analytical development scientist supporting the CDMO offering from our company.

He studied synthetic organometallic chemistry and received his Ph.D. from the University of Iowa.

Jeffery Carroll

Jeffery Carroll


Senior Scientist, Team Lead ADC Express, Process and Analytical Development

Jeffery (Jeff) Carroll has been with Merck for more than seven years and is currently the team leader for ADC Express in process and analytical development for bio-conjugation/bio-organic contract manufacturing. He is an expert synthetic chemist and a champion for utilizing new linker chemistries to accelerate early ADC development. Jeff previously worked at Monsanto Co. and Pfizer Inc., specializing in small molecule synthesis for herbicides and pharmaceuticals which is showcased in 11 publications and 12 patents to date.

Jeff has a B.S. in chemistry from the University of Illinois-Champaign, Champaign, IL, and an M.S. in organic synthesis from Rice University, Houston, TX with his thesis on perfluoro-cholesterol analogs as a treatment for familial hypercholesterolemia.

Webinar Information

Pharma and biopharma manufacturing

  • Antibody drug conjugate manufacturing
  • Duration:1h

  • Language:English

  • Session 1:presented April 21, 2022

    Watch Now

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?